000			nab a22 7a 4500
999			_c15983 _d15983
003			PC15983
005			20210304105008.0
008			200611b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia
245	0	0	_aCombination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. _h[artículo]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology, _c2014
300			_a32(20):2173-80.
500			_aFormato Vancouver: Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014 Jul 10;32(20):2173-80.
501			_aPMID: 24888806 PMC4879712
504			_aContiene 23 referencias
520			_aPurpose: To construct and validate among patients with multiple myeloma (MM) who were treated with intensive therapy a prognostic index of early MM progression-related death. Patients and methods: Patient-level data from the Intergroupe Francophone du Myélome (IFM) 2005-01 trial (N = 482) were used to construct the prognostic index. The event was MM progression-related death within 2 years from treatment initiation. The index was validated using data from three other trials: the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) 26866138-MMY-3006 trial (N = 480), the Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA)-GEMMENOS65 trial (N = 390), and the Hemato-Oncologie voor Volwassenen Nederland (HOVON) -65/German-Speaking Myeloma Multicenter Group (GMMG) -HD4 trial (N = 827). Results: The risk of early MM progression-related death was related to three independent prognostic variables: lactate dehydrogenase (LDH) higher than than normal, International Staging System 3 (ISS3), and adverse cytogenetics [t(4;14) and/or del(17p)]. These three variables enabled the definition of an ordinal prognostic classification composed of four scores (0 to 3). Patients with a score of 3, defined by the presence of t(4;14) and/or del(17p) in addition to ISS3 and/or high LDH, comprised 5% (20 of 387 patients) to 8% (94 of 1,139 patients) of the patients in the learning and validation samples, respectively, and they had a very poor prognosis. When applied to the population of 855 patients who had received bortezomib-based induction therapy in the four trials, the prognostic classification was also able to segregate patients into four categories, with a very poor prognosis attributed to patients with a score of 3. Conclusion: Our model allows the simple definition of a subgroup of MM patients at high risk of early MM progression-related death despite the use of the most modern and effective strategies.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879712/ _yAcceso libre
942			_2ddc _cART _n0